fda glp-1 compounding enforcement september 2025 Beyond the Headlines: Warning Letters to Compounders FDA is moving to restrict

[DOI] [PMC free article] [PubMed] [Google Scholar] 190.Zhang X., Pang G., Sun T., Liu X., Pan H., Zhang Y., Liu J., Chang J., Wang H., Liu D

Either way, considering the cost of these medications and the prevalence of both diabetes or obesity within a population, there is a potential for significant costs for the payers employers, employees or health insurance companies

As the number of diabetic patients continues to grow globally, this disease has become a major and growing challenge in global public health

Important warnings include thyroid tumor risk, pancreatitis, gallbladder disease, dehydration-related kidney injury, and hypoglycemia when used with insulin or sulfonylureas